ATE184191T3 - Pharmazeutische formulierung - Google Patents

Pharmazeutische formulierung Download PDF

Info

Publication number
ATE184191T3
ATE184191T3 AT94901148T AT94901148T ATE184191T3 AT E184191 T3 ATE184191 T3 AT E184191T3 AT 94901148 T AT94901148 T AT 94901148T AT 94901148 T AT94901148 T AT 94901148T AT E184191 T3 ATE184191 T3 AT E184191T3
Authority
AT
Austria
Prior art keywords
pct
date
pharmaceutical formulation
sec
active agent
Prior art date
Application number
AT94901148T
Other languages
German (de)
English (en)
Inventor
Christer Nystroem
Lennart Paalzow
Sten-Magnus Aquilonius
Original Assignee
Neopharma Production Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production Ab filed Critical Neopharma Production Ab
Publication of ATE184191T3 publication Critical patent/ATE184191T3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94901148T 1992-11-30 1993-11-29 Pharmazeutische formulierung ATE184191T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system

Publications (1)

Publication Number Publication Date
ATE184191T3 true ATE184191T3 (de) 1999-09-15

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94901148T ATE184191T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung

Country Status (15)

Country Link
US (1) US5635213A (enExample)
EP (1) EP0670713B3 (enExample)
JP (1) JP3661703B2 (enExample)
AT (1) ATE184191T3 (enExample)
AU (1) AU688290B2 (enExample)
CA (1) CA2150464C (enExample)
DE (2) DE122005000021I1 (enExample)
DK (1) DK0670713T3 (enExample)
ES (1) ES2137350T7 (enExample)
FR (1) FR04C0024I2 (enExample)
GR (1) GR3031988T3 (enExample)
NL (1) NL300169I1 (enExample)
NZ (1) NZ258276A (enExample)
SE (1) SE9203594D0 (enExample)
WO (1) WO1994012153A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8779094B2 (en) 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10335540B2 (en) 2012-04-17 2019-07-02 Micrel Medical Devices S.A. Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2739536T3 (es) 2014-10-21 2020-01-31 Abbvie Inc Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP2019523249A (ja) * 2016-07-20 2019-08-22 アッヴィ・インコーポレイテッド レボドパ及びカルビドパ腸管ゲル、並びに使用方法
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
ES2137350T7 (es) 2017-11-13
AU5583694A (en) 1994-06-22
SE9203594D0 (sv) 1992-11-30
DK0670713T3 (da) 2000-03-20
EP0670713A1 (en) 1995-09-13
CA2150464A1 (en) 1994-06-09
EP0670713B3 (en) 2016-10-05
DE69326350T3 (de) 2018-01-11
GR3031988T3 (en) 2000-03-31
DE69326350D1 (de) 1999-10-14
JPH08504764A (ja) 1996-05-21
NL300169I1 (nl) 2005-03-01
NZ258276A (en) 1996-09-25
WO1994012153A1 (en) 1994-06-09
ES2137350T3 (es) 1999-12-16
DE69326350T2 (de) 2000-01-27
AU688290B2 (en) 1998-03-12
FR04C0024I1 (enExample) 2004-03-12
US5635213A (en) 1997-06-03
CA2150464C (en) 2002-02-05
DE122005000021I1 (de) 2006-02-23
JP3661703B2 (ja) 2005-06-22
EP0670713B1 (en) 1999-09-08
FR04C0024I2 (enExample) 2010-12-31

Similar Documents

Publication Publication Date Title
DE69326350D1 (de) Pharmazeutische formulierung
DE69305328D1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
ES2052016T3 (es) Composicion emulsionada.
TW347339B (en) Oral delivery of discrete units
ATE333867T1 (de) Emulgierte arzneistoffabgabesysteme
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DE59405590D1 (de) Kosmetische und medizinische topische zubereitungen
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
ATE116543T1 (de) Osmotisches dosiersystem zur verabreichung von flüssigen arzneimitteln.
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
IE873125L (en) Benzimidazole derivatives
GB8603523D0 (en) Slow release formulation
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
DE59505047D1 (de) Versprühbare filmbildende wirkstoffabgabesysteme zur anwendung an pflanzen
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
DK0668755T3 (da) Frembringelsesanorning, der har indkapslede excipienser
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
ITMI931326A1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
HRP20020332B1 (hr) Oralne otopine koje sadrže galantamin i sladilo
ES2193562T3 (es) Dispositivo de dosificacion.
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
DK0804152T3 (da) Lactulose-pastiller
DE59406568D1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel